Forget Wegovy and Zepbound. Never mind CagriSema, and even retatrutide. The latest big name in obesity is eloraTZP. Data ...
Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess ...
Zealand and Roche's petrelintide peaks at 10.7% weight loss at its middle dose in Ph2, trailing Lilly's eloralintide at 20.1% ...
Beam Therapeutics sued YolTech's Yuxuan Wu & Zi Jun Wang and Serapha Bio for allegedly stealing trade secrets related to ...
Former House majority leader Eric Cantor has been chosen as PhRMA’s next CEO, according to two sources familiar ...
UniQure's shares were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy ...
NCI director Ned Sharpless as MD and Andrew Witty as chairman, while raising a $100M second opportunities fund.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results